ARTCLINE appoints Dirk Hessel as managing director

German privately-held biotech ARTCLINE Bio-Therapies today announced the appointment of Dirk Hessel as additional managing director of the company.

With his extensive experience in sales and marketing of medical devices and biopharmaceutical products, he will lead the company together with the current management through its next phase of growth and drive the commercialization of the innovative ARTICE therapy.

Before joining ARTCLINE, Mr Hessel held leading positions in the pharmaceutical and biotechnology industry. Most recently, he was chief executive of a German biotech company which developed a liquid biopsy assay for the early detection and treatment monitoring of breast cancer patients. Prior to that, as CEO at CO.DON AG, he was responsible for the European Medicines Agency (EMA) approval of an advanced therapy medicinal product (ATMP) in cell and gene therapy. Before entering the biotech industry, Mr Hessel spent more than 15 years of his professional career at Bayer (BAYN: DE) and Grünenthal GmbH in strategic and international management positions.